The latest price target for Connect Biopharma Hldgs (NASDAQ:CNTB) was reported by HC Wainwright & Co. on September 6, 2024. The analyst firm set a price target for $8.00 expecting CNTB to rise to within 12 months (a possible 716.33% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Connect Biopharma Hldgs (NASDAQ:CNTB) was provided by HC Wainwright & Co., and Connect Biopharma Hldgs reiterated their buy rating.

There is no last upgrade for Connect Biopharma Hldgs

The last downgrade for Connect Biopharma Holdings Ltd happened on May 5, 2022 when Piper Sandler changed their price target from $25 to $1.5 for Connect Biopharma Holdings Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Connect Biopharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Connect Biopharma Hldgs was filed on September 6, 2024 so you should expect the next rating to be made available sometime around September 6, 2025.

While ratings are subjective and will change, the latest Connect Biopharma Hldgs (CNTB) rating was a reiterated with a price target of $8.00 to $8.00. The current price Connect Biopharma Hldgs (CNTB) is trading at is $0.98, which is out of the analyst’s predicted range.